Pharmacological treatment of obesity

Mancini, Márcio C.; Halpern, Alfredto

doi:10.1590/s0004-27302006000200024

Cited by 44 publications

(24 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies in overweight and obese women with urinary incontinence have shown that a modest (7-8%) weight reduction can improve the frequency of urinary incontinence [11]. Unlike urinary incontinence, the relation between FI and obesity has not been clearly established.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Functional Evaluation of Obese Patients with Symptoms of Fecal Incontinence Using Anorectal Electromanometry

Da¹,

Dmr²,

Kurachi³

et al. 2017

J Obes Weight Loss Ther

View full text Add to dashboard Cite

Obesity is a modifiable risk factor to fecal incontinence (FI) and weight loss result in improvement in the frequency and severity of FI.Introduction: Fecal incontinence (FI) has a multifactorial etiology and is most common in women. The prevalence is variable, though generally underestimated due to embarrassment. Since the incidence of pelvic floor disorders is higher among obese individuals, obesity may be considered a modifiable risk factor for FI. Weight loss seems to result in improvement in the frequency and severity of FI episodes. However, little has been published on FI in obese subjects and on its impact on quality of life in this patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Obesity is a modifiable risk factor for FI because obese subjects have higher incidences of pelvic floor dysfunctions [11]. Weight loss in obese women appear to result in improvements in both the frequency and severity of FI episodes.…”

Section: Introductionmentioning

confidence: 99%

Functional Evaluation of Obese Patients with Symptoms of Fecal Incontinence Using Anorectal Electromanometry

Da¹,

Dmr²,

Kurachi³

et al. 2017

J Obes Weight Loss Ther

View full text Add to dashboard Cite

show abstract

“…Essa medicação também possui liberação da Anvisa (Agência Nacional de Vigilância Sanitária), porém nunca foi comercializada no Brasil (32). O topiramato é uma medicação inicialmente liberada para tratamento da epilepsia, que atualmente também é amplamente prescrita para a profilaxia da enxaqueca.…”

Section: Fentermina/topiramatounclassified

Progressos recentes e novas perspectivas em farmacoterapia da obesidade

Faria

Mancini

Melo

et al. 2010

Arq Bras Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

1sumário O aumento da prevalência da obesidade, nas últimas décadas, é alarmante, o que implica um grande número de pacientes sob risco de complicações metabólicas e cardiovasculares associadas. A eficácia modesta a longo prazo das modificações de estilo de vida isoladamente exige a necessidade de intervenções mais agressivas, seja por meio do uso adjuvante de medicamentos ou da abordagem mais radical cirúrgica. A cirurgia bariátrica, embora até hoje tenha se mostrado o método mais efetivo de tratamento dessa enfermidade, pode estar associada a complicações nutricionais e metabólicas ainda não totalmente esclarecidas. Contrasta com esse fato a disponibilidade limitada de agentes antiobesidade atualmente no mercado, além de fatos históricos que envolveram a suspensão de alguns fármacos previamente existentes, por questões de segurança. Este artigo tem como objetivo apresentar dados recentes de estudos clínicos de novas drogas propostas para o tratamento da obesidade com perspectivas breves de serem lançadas no mercado, caso passem pela aprovação das agências regulatórias. Nesta revisão serão discutidas a eficácia e a segurança desses fármacos, que incluem a lorcaserina (agonista serotoninérgico seletivo 5-HT2c), tesofensina (inibidor triplo de recaptação de monoa minas), liraglutide (análogo do GLP-1) e cetilistate (inibidor de lipases gastrointestinais), além das combinações de bupropiona/naltrexona, bupropiona/zonisamida, fentermina/topiramato e pramlintide/metreleptina. Arq Bras Endocrinol Metab. 2010;54(6):516-29 Descritores Obesidade; farmacoterapia; agentes antiobesidade summary Obesity prevalence has risen dramatically over the past decades, which poses a great number of patients at risk of metabolic and cardiovascular complications. Long-term efficacy of lifestyle modification isolated has shown to be modest which, therefore, urges the need of more aggressive interventions such as adjuvant pharmacotherapy or the more radical surgical approach. Bariatric surgery has proven to date to be the most effective treatment, although it may be associated with nutritional and metabolic complications not yet completely recognized. By contrast, there is limited availability of antiobesity agents currently in the market, as well as historical facts involving the suspension of previously existing medications due to safety concerns. This article aims to present recent data on clinical trials of novel weight-loss drugs with short perspective to enter the market, if approved by the regulatory agencies. This review will discuss the efficacy and safety of these compounds, which include lorcaserin (selective serotonin 5-HT2c agonist), tesofensine (triple monoamine reuptake inhibitor), liraglutide (GLP-1 analogue) and cetilistat (gastrointestinal lipase inhibitor), as well as the combination therapies of bupropion/ naltrexone, bupropion/zonisamide, phentermine/topiramate and pramlintide/metreleptin. Arq Bras Endocrinol Metab. 2010;54(6):516-29

show abstract

“…Furthermore, it is an adjunct to other strategies to treat obese individuals, as it causes weight loss both in laboratory animals and humans (Leombruni et al, 2008;Mancini & Halpern, 2006;Mitchell, Zwaan, & Roerig, 2003). However, the mechanisms underlying the effects of FLX in feeding behavior are affected by factors such as stress and hunger (Hsiao, Chung, Tong, & Cheng, 2006;Gamaro et al, 2008;Placidi et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Sexual experience did not affect the long-term sexual behavior inhibition of male rats treated with fluoxetine.

Habr

Dias

Teodorov

et al. 2009

Psychology & Neuroscience

View full text Add to dashboard Cite

Antidepressants, including tricyclics, monoamine oxidase inhibitors and selective serotonin reuptake inhibitors cause sexual dysfunctions such as decreased sexual desire, erectile difficulties, and delayed ejaculation. Studies have shown that treatment with fluoxetine inhibits several components of sexual behavior in male rats. It is known that sexual experience improves the sexual behavior of male rats. Thus, the effects of sexual experience were examined in male rats during long-term treatment with fluoxetine or vehicle. Rats treated with 10mg/kg fluoxetine or vehicle daily (28 days) were observed for sexual behavior at the 14th, 21st, and 28th day of treatment. Long-term administration of fluoxetine increased the mount latency in control rats in the first session; no differences were observed in other parameters on the same day. Still in the control group, the mount and intromission latencies gradually decreased, whereas the number of intromissions and ejaculations increased over the sessions. The group in long-term treatment with fluoxetine also showed reduced mount and intromission latencies, although latencies remained significantly higher as compared to the control group. Fluoxetine-treated rats showed increased mount and intromission rates on the 28th day of treatment in relation to the first day. These data suggest that the impairment caused by long-term treatment with fluoxetine persists throughout the sessions despite the rats' sexual experience.

show abstract

Pharmacological treatment of obesity

Cited by 44 publications

References 73 publications

Functional Evaluation of Obese Patients with Symptoms of Fecal Incontinence Using Anorectal Electromanometry

Functional Evaluation of Obese Patients with Symptoms of Fecal Incontinence Using Anorectal Electromanometry

Progressos recentes e novas perspectivas em farmacoterapia da obesidade

Sexual experience did not affect the long-term sexual behavior inhibition of male rats treated with fluoxetine.

Contact Info

Product

Resources

About